SPC25 and ovarian carcinoma: SPC25 is associated with cisplatin resistance and stemness in HNSCC [54], promotes stemness and predicts survival in LUAD [55], mediates immune escape via glutamine metabolism in LUAD [56], and its inhibition overcomes stemness and enhances platinum sensitivity in ovarian cancer [57].